GlassScriptPhysician profile
Reyna S Perry
NPI 1114621307
$9,285.73
in general payments reported to CMS, 2019-2025
32 companies · $3,207 in 2025
The $3,207 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,740 · 2024: $3,339 · 2025: $3,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,274 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,273.58 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,669.53 | 2023-2025 | |
| Axsome Therapeutics, INC. | $984.53 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $935.77 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $927.91 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $802.48 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $517.50 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $471.81 | 2023-2025 | Invega Sustenna, Xarelto, Spravato |
| Neurocrine Biosciences, INC. | $436.68 | 2023-2025 | Ingrezza |
| Corium, LLC | $344.86 | 2023-2025 | Azstarys |
| Lundbeck LLC | $261.84 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $175.11 | 2024-2025 | Cobenfy |
| Bioventus LLC | $155.32 | 2025 | Exogen Ultrasound Bone Healing System, Durolane |
| Braeburn INC. | $133.23 | 2023 | Brixadi |
| Vanda Pharmaceuticals INC. | $125.85 | 2024-2025 | Fanapt |
| Eisai INC. | $124.94 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $124.56 | 2025 | Vyvgart |
| Supernus Pharmaceuticals, INC. | $116.50 | 2024-2025 | Qelbree |
| Stryker Corporation | $116.12 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $106.90 | 2023-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $102.64 | 2023 | |
| Indivior INC. | $101.45 | 2023-2024 | Perseris |
| Sanofi-Aventis U.S. LLC | $90.93 | 2025 | |
| Noven Pharmaceuticals, INC. | $81.49 | 2023 | Xelstrym |
| Sk Life Science, INC. | $75.42 | 2025 | Xcopri |
| Aimmune Therapeutics, INC. | $60.59 | 2025 | Zenpep |
| Ironshore Pharmaceuticals INC. | $59.35 | 2023-2024 | Jornay Pm |
| Sage Therapeutics, LLC | $48.53 | 2025 | Zurzuvae |
| Tris Pharma INC | $42.59 | 2024-2025 | Dyanavel Xr |
| Luye Pharma (USA) LTD. | $29.84 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $28.16 | 2023 | Xelstrym |
| Bausch Health US, LLC | $17.02 | 2025 | Aplenzin |
| Avion Pharmaceuticals | $16.28 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reyna Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.